Investors in Soleno Therapeutics Have Chance to Lead Fraud Lawsuit Over Losses

Opportunity for Soleno Therapeutics Shareholders

Background
Soleno Therapeutics, Inc. (NASDAQ: SLNO) has recently come under scrutiny due to potential securities fraud allegations. The Law Offices of Howard G. Smith has opened an opportunity for investors who suffered financial losses in Soleno to take a lead role in filing a class-action lawsuit against the firm. This initiative is particularly crucial for those who invested between March 26, 2025, and November 4, 2026.

Details of the Lawsuit
The lawsuit stems from claims that Soleno Therapeutics failed to adequately inform its shareholders about significant safety concerns related to its Phase 3 clinical trial program for DCCR. The specific allegations include that the company misrepresented vital evidence regarding the safety of their product and the associated risks connected to its administration. These concerns reportedly included:

1. Misrepresentation of Safety Evidence: The complaint alleges that Soleno downplayed safety risks, particularly those regarding excess fluid retention in clinical trial participants, which could significantly affect the treatment's viability.

2. Higher Safety Risks: The implications of the alleged misinformation suggest that the use of DCCR to manage hyperphagia in individuals with Prader-Willi syndrome (PWS) may carry greater safety risks than disclosed to investors, impacting investor confidence and company credibility.

3. Commercial Viability Issues: The lawsuit takes issue with the commercial viability of DCCR, arguing that undisclosed risks have the potential to lead to adverse outcomes post-launch, such as high patient dropout rates and negative reactions from prescribers and regulatory bodies.

4. Misleading Positive Statements: The legal filing asserts that Soleno's management made misleading statements regarding the company’s performance, leading investors to have an inaccurate perception of the firm's operational potential and future growth prospects.

Participating in the Lawsuit
Investors who feel they were financially impacted by Soleno Therapeutics's actions are encouraged to reach out to the Law Offices of Howard G. Smith before May 5, 2026. This date marks the deadline for participating as a lead plaintiff in the ongoing class action. Interested individuals can easily initiate contact via email or phone to discuss their legal rights and options.

Contact Information
To learn more about the class action or to address any inquiries regarding your potential involvement, it's advised to contact Howard G. Smith, who oversees this case. The firm provides various avenues for communication, thus ensuring that affected shareholders can explore their options without delay. The Law Offices of Howard G. Smith emphasize that you are not obligated to take any immediate action but may also choose to retain personal legal representation.

Conclusion
In light of these developments, shareholders of Soleno Therapeutics hold a critical opportunity to pursue justice regarding their financial losses. By joining this class-action lawsuit, investors can seek redress and hold the company accountable for the alleged discrepancies in representation and corporate conduct. This case underscores the importance of corporate transparency and the need for robust legal remedies for harmed investors.